Results 21 to 30 of about 1,117 (151)
Heterocycles, 2012 The Fe(III)-catalyzed three-component coupling of arylamines (I), aryl aldehydes (II) and arylacetylenes (III) affords 2,4-diarylquinolines (IV) in good yields.
Biao Xiong, Yuqiang Ding, Qijun Song
exaly +2 more sources
A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis. [PDF]
J Clin Lab AnalThe use of delamanid and bedaquilineis steadily increasing in the treatment of MDR‐ and XDR‐ tuberculosis. These two recently developed drugs provide a tangible possibility for enhancing the prognosis of these patients. This narrative review aimed to present a concise overview of the existing information regarding delamanid and bedaquiline.
Ahmad Khosravi N +3 more
europepmc +2 more sources
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis [PDF]
TrialsBackground The standard of care (SOC) treatment for drug-susceptible pulmonary tuberculosis (DS-TB) consists of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE).
Linda J. Harrison +26 more
doaj +2 more sources
Pharmaceuticals, 2021 Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a curable airborne disease currently treated using a drug regimen consisting of four drugs.
Klaudia T. Angula +2 more
doaj +1 more source
STAR Protocols, 2022 Summary: Here, we present a ligand-enabled metallaphotoredox Suzuki-Miyaura cross-coupling protocol for the facile synthesis of diarylmethanes. Specifically, we describe the preparation of a unique class of ligands, 2,4-diarylquinolines, and demonstrate ...
Jianbin Li, Chia-Yu Huang, Chao-Jun Li
doaj +1 more source
Molecules, 2022 Bedaquiline is a novel adenosine triphosphate synthase inhibitor anti-tuberculosis drug. Bedaquiline belongs to the class of diarylquinolines, which are antituberculosis drugs that are quite different mechanistically from quinolines and flouroquinolines.
Muaaz Mutaz Alajlani
doaj +1 more source
The pipeline of new molecules and regimens against drug-resistant tuberculosis
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021 The clinical development and regulatory approval of bedaquiline, delamanid and pretomanid over the last decade brought about significant progress in the management of drug-resistant tuberculosis, providing all-oral regimens with favorable safety profiles.
Todd A. Black, Ulrike K. Buchwald
doaj +1 more source
Binding properties of the anti-TB drugs bedaquiline and TBAJ-876 to a mycobacterial F-ATP synthase
Current Research in Structural Biology, 2022 Tuberculosis (TB), the deadly disease caused by Mycobacterium tuberculosis (Mtb), kills more people worldwide than any other bacterial infectious disease. There has been a recent resurgence of TB drug discovery activities, resulting in the identification
Alexander Krah +2 more
doaj +1 more source
In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase Inhibitor [PDF]
Antimicrobial Agents and Chemotherapy, 2007 ABSTRACT The diarylquinoline R207910 is in clinical development for tuberculosis treatment. The MIC 50 for 41 drug-susceptible and 44 multidrug-resistant Mycobacterium tuberculosis clinical isolates was 0.032 μg/ml.
Huitric, Emma +3 more
openaire +3 more sources